"Esters" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds derived from organic or inorganic acids in which at least one hydroxyl group is replaced by an –O-alkyl or other organic group. They can be represented by the structure formula RCOOR’ and are usually formed by the reaction between an acid and an alcohol with elimination of water.
| Descriptor ID |
D004952
|
| MeSH Number(s) |
D02.241.400
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Esters".
Below are MeSH descriptors whose meaning is more specific than "Esters".
This graph shows the total number of publications written about "Esters" by people in this website by year, and whether "Esters" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2017 | 1 | 3 | 4 |
| 2018 | 2 | 2 | 4 |
| 2019 | 0 | 2 | 2 |
| 2020 | 1 | 6 | 7 |
| 2021 | 5 | 3 | 8 |
To return to the timeline, click here.
Below are the most recent publications written about "Esters" by people in Profiles.
-
SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion. Trials. 2021 Aug 19; 22(1):550.
-
Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease. J Virol. 2021 10 13; 95(21):e0097521.
-
The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19. mBio. 2021 08 31; 12(4):e0097021.
-
Determination of camostat and its metabolites in human plasma - Preservation of samples and quantification by a validated UHPLC-MS/MS method. Clin Biochem. 2021 Oct; 96:56-62.
-
Identification of 13 Guanidinobenzoyl- or Aminidinobenzoyl-Containing Drugs to Potentially Inhibit TMPRSS2 for COVID-19 Treatment. Int J Mol Sci. 2021 Jun 30; 22(13).
-
SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. Cell Rep. 2021 07 20; 36(3):109415.
-
Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat. J Virol. 2021 09 09; 95(19):e0086121.
-
A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID-19. Clin Transl Sci. 2021 09; 14(5):1967-1976.
-
Disruption of disulfides within RBD of SARS-CoV-2 spike protein prevents fusion and represents a target for viral entry inhibition by registered drugs. FASEB J. 2021 06; 35(6):e21651.
-
COVID-19 face masks: A new source of human and environmental exposure to organophosphate esters. Environ Int. 2021 09; 154:106654.